[go: up one dir, main page]

EA201390804A1 - Лекарственная форма лакозамида для приема один раз в сутки - Google Patents

Лекарственная форма лакозамида для приема один раз в сутки

Info

Publication number
EA201390804A1
EA201390804A1 EA201390804A EA201390804A EA201390804A1 EA 201390804 A1 EA201390804 A1 EA 201390804A1 EA 201390804 A EA201390804 A EA 201390804A EA 201390804 A EA201390804 A EA 201390804A EA 201390804 A1 EA201390804 A1 EA 201390804A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lacosamide
once
dosage form
admission
day
Prior art date
Application number
EA201390804A
Other languages
English (en)
Other versions
EA029180B1 (ru
Inventor
Вилли Кавелло
Мартин Александер Шуберт
Original Assignee
Юсб Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390804(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP10193561A external-priority patent/EP2468261A1/en
Application filed by Юсб Фарма Гмбх filed Critical Юсб Фарма Гмбх
Publication of EA201390804A1 publication Critical patent/EA201390804A1/ru
Publication of EA029180B1 publication Critical patent/EA029180B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Лекарственная форма лакозамида с модифицированным высвобождением для приема один раз в сутки.
EA201390804A 2010-12-02 2011-12-01 Лекарственная форма лакозамида для приема один раз в сутки EA029180B1 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US41915810P 2010-12-02 2010-12-02
US41915310P 2010-12-02 2010-12-02
EP10193559 2010-12-02
EP10193561A EP2468261A1 (en) 2010-12-02 2010-12-02 Formulation of lacosamide
US201161444447P 2011-02-18 2011-02-18
US201161444439P 2011-02-18 2011-02-18
US201161485354P 2011-05-12 2011-05-12
US201161485361P 2011-05-12 2011-05-12
PCT/EP2011/006027 WO2012072256A2 (en) 2010-12-02 2011-12-01 Once daily formulation of lacosamide

Publications (2)

Publication Number Publication Date
EA201390804A1 true EA201390804A1 (ru) 2013-10-30
EA029180B1 EA029180B1 (ru) 2018-02-28

Family

ID=46172318

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390804A EA029180B1 (ru) 2010-12-02 2011-12-01 Лекарственная форма лакозамида для приема один раз в сутки

Country Status (14)

Country Link
US (4) US20130251813A1 (ru)
EP (3) EP3766485A1 (ru)
JP (2) JP6027539B2 (ru)
KR (1) KR101980386B1 (ru)
CN (1) CN103561727B (ru)
AU (1) AU2011335415B2 (ru)
BR (1) BR112013013525A2 (ru)
CA (1) CA2817654A1 (ru)
EA (1) EA029180B1 (ru)
IL (1) IL226231B (ru)
MX (1) MX2013005974A (ru)
NZ (1) NZ610701A (ru)
WO (2) WO2012072256A2 (ru)
ZA (1) ZA201303289B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
AU2007260207B2 (en) 2006-06-15 2012-11-08 Ucb Pharma Gmbh Pharmaceutical composition with synergistic anticonvulsant effect
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
EP2529731A1 (en) * 2011-06-01 2012-12-05 Nitto Denko Corporation Particulate preparation and method for producing the same
US8779355B2 (en) 2011-12-28 2014-07-15 Quest Diagnostics Investments, Inc. Methods for detecting lacosamide by mass spectrometry
KR101732731B1 (ko) 2013-04-02 2017-05-08 주식회사 바이오파마티스 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물
WO2014180895A1 (en) * 2013-05-08 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of lacosamide
EP2878296A1 (en) * 2013-11-29 2015-06-03 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam
EP3074004A2 (en) * 2013-11-29 2016-10-05 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam
US20150328246A1 (en) * 2014-05-16 2015-11-19 Vivus, Inc. Orally administratable formulations for the controlled release of a pharmacologically active agent
US20180021307A1 (en) * 2015-02-20 2018-01-25 Ucb Biopharma Sprl Combination Treatment
JO3543B1 (ar) * 2015-09-28 2020-07-05 Applied Pharma Res تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
WO2017058869A1 (en) 2015-09-29 2017-04-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
WO2018062955A1 (ko) * 2016-09-29 2018-04-05 에스케이케미칼(주) 라코사미드 서방성 제제
CN106551900A (zh) * 2016-12-05 2017-04-05 北京万全德众医药生物技术有限公司 一种拉科酰胺口服溶液及其制备工艺
RS65112B1 (sr) 2016-12-09 2024-02-29 Alexza Pharmaceuticals Inc Alprazolam za upotrebu u lečenju epilepsije
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
JP2021511893A (ja) 2018-02-02 2021-05-13 アレクザ・ファーマシューティカルズ・インコーポレイテッドＡｌｅｘｚａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 電気式凝縮エアロゾル装置
KR102083241B1 (ko) 2018-02-14 2020-03-02 환인제약 주식회사 라코사미드를 함유하는 약제학적 서방성 조성물
CN110833528A (zh) * 2018-08-17 2020-02-25 北京万全德众医药生物技术有限公司 一种拉科酰胺脂质体冻干粉针剂及其制备方法
CN109010301B (zh) * 2018-09-05 2021-01-26 上海上药第一生化药业有限公司 一种拉考沙胺晶型ii片剂及其制备方法和应用
CN112043681B (zh) * 2019-06-06 2022-04-12 上海奥科达生物医药科技有限公司 一种拉考沙胺药物组合物及其药物制剂
US12042474B2 (en) 2019-06-06 2024-07-23 Shanghai Aucta Pharmaceuticals Co., Ltd. Lacosamide pharmaceutical composition and dosage form thereof
CN112022804A (zh) * 2020-09-28 2020-12-04 健民药业集团股份有限公司 一种拉考沙胺口服溶液及制备方法
EP4309648A4 (en) * 2021-03-17 2025-03-05 Shanghai Yonsun Biotechnology Co., Ltd. PHARMACEUTICAL LACOSAMIDE COMPOSITION, MANUFACTURING PROCESS THEREOF AND APPLICATIONS THEREOF
WO2024054987A1 (en) * 2022-09-08 2024-03-14 The Children's Hospital Of Philadlphia Gpcr latrophilin-3 as biomarker for detecting increased risk for mild brain injury and methods of use thereof for diagnosis and treatment of the same
CN115581676A (zh) * 2022-09-30 2023-01-10 澳美制药(苏州)有限公司 拉考沙胺片剂及其制备工艺

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2218024T3 (es) 1996-03-15 2004-11-16 Research Corporation Technologies, Inc Derivados de aminoacido enantiomerico anticonvulsionante.
ES2184300T3 (es) 1997-07-15 2003-04-01 Res Corp Technologies Inc Derivados de aminoacidos utiles para tratar el accidente vascular encefalico.
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
US7794987B2 (en) 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
CA2562937A1 (en) 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
NZ552651A (en) 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
JP2006124385A (ja) * 2004-09-30 2006-05-18 Takeda Chem Ind Ltd 放出制御製剤
US20060105663A1 (en) * 2004-10-04 2006-05-18 Stefan Greulich Polymer assemblies with decorative surfaces
JP5739080B2 (ja) * 2005-01-27 2015-06-24 アレムビック・リミテッドＡｌｅｍｂｉｃ Ｌｉｍｉｔｅｄ レベチラセタムの徐放性製剤
AR057643A1 (es) 2005-01-28 2007-12-12 Sanol Arznei Schwarz Gmbh Lacosamida para terapia adjunta
AU2006269225B2 (en) * 2005-07-07 2011-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
EP1920780A1 (en) 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
EP1925314A1 (en) 2006-11-22 2008-05-28 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
AU2007260207B2 (en) 2006-06-15 2012-11-08 Ucb Pharma Gmbh Pharmaceutical composition with synergistic anticonvulsant effect
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
ATE511392T1 (de) * 2007-01-11 2011-06-15 Xenoport Inc Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
WO2009069089A1 (en) 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
US20090143362A1 (en) 2007-12-04 2009-06-04 Barabde Umesh Vinayakrao Carbamazepine formulations
DE102008059155A1 (de) * 2008-11-27 2010-06-02 Ratiopharm Gmbh Trockenverarbeitung und neue Formen von Lacosamid
KR100980999B1 (ko) * 2008-11-28 2010-09-07 기아자동차주식회사 차량용 시거라이터조립체
WO2010148300A1 (en) 2009-06-19 2010-12-23 The University Of North Carolina At Chapel Hill Methods of treatment of neurological disorders
WO2011037833A2 (en) 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US10786464B2 (en) * 2009-11-03 2020-09-29 Lupin Limited Modified release formulation of lacosamide
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide

Also Published As

Publication number Publication date
EP2645997B1 (en) 2022-08-10
NZ610701A (en) 2015-06-26
US20150104507A1 (en) 2015-04-16
EP3766485A1 (en) 2021-01-20
CN103561727B (zh) 2018-03-27
JP6357687B2 (ja) 2018-07-18
EP2646001A2 (en) 2013-10-09
US20130251813A1 (en) 2013-09-26
WO2012084126A2 (en) 2012-06-28
WO2012072256A3 (en) 2014-01-23
US20190054009A1 (en) 2019-02-21
AU2011335415A1 (en) 2013-06-20
JP6027539B2 (ja) 2016-11-16
KR20150034579A (ko) 2015-04-03
ZA201303289B (en) 2014-02-26
JP2017031206A (ja) 2017-02-09
BR112013013525A2 (pt) 2016-10-18
EA029180B1 (ru) 2018-02-28
CN103561727A (zh) 2014-02-05
AU2011335415B2 (en) 2016-05-19
IL226231A0 (en) 2013-07-31
WO2012072256A2 (en) 2012-06-07
KR101980386B1 (ko) 2019-05-20
IL226231B (en) 2018-01-31
CA2817654A1 (en) 2012-06-07
EP2645997A2 (en) 2013-10-09
WO2012084126A3 (en) 2013-05-02
JP2013545762A (ja) 2013-12-26
MX2013005974A (es) 2013-07-29
US20190008758A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
UY34411A (es) Inmunoenlazantes dirigidos contra esclerostina
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CO7020912A2 (es) Inhibidores de bromodominios
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
DK2632493T3 (da) Lægemiddelindgivelsessammensætninger
EA201270722A1 (ru) Формы рифаксимина и их применение
EP2636736A4 (en) NOVEL ANTI-DR5 ANTIBODY
CL2012003385A1 (es) Tratamiento para la incontinencia.
CL2011000481S1 (es) Aplicador para cuidado oral.
EP2705181A4 (en) PHARMACEUTICAL COMBINATION COMPOSITIONS AND ITS USE
EP2616076A4 (en) PHARMACEUTICAL COMPOSITIONS
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
EP2922877A4 (en) IMPROVED PEPTIDATE MEDICINES
EP2758052A4 (en) PHARMACEUTICAL COMPOSITIONS
HRP20170928T1 (hr) Inhibitori kinurenin-3-monooksigenaze, farmaceutski pripravci, i postupci za njihovu upotrebu
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
BR112013014644A2 (pt) composição farmacêutica e complexo
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
MX347855B (es) Derivados de anilina, su preparación y su aplicación terapéutica.
UY34078A (es) Composiciones farmacéuticas y métodos para tratar el cáncer
EP2769718A4 (en) MEDICAL COMPOSITION
UY34829A (es) Nueva dosificación y formulación
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU